57th ASH Annual Meeting and Exposition (December 5-8, 2015): 901. Health Services and Outcomes Research

Health Services and Outcomes Research – Non-Malignant Conditions Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Association Between Acute Leukoencephalopathy and Long-Term Neurobehavioral and Brain Imaging Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only

Yin Ting Cheung, PhD¹^*, Noah D. Sabin, MD, JD²^*, Wilburn E. Reddick, PhD²^*, Deepa Bhojwani, MD³^*, Wei Liu, PhD⁴^*, Tara M. Brinkman, PhD¹^*, John O. Glass, PhD²^*, DeoKumar Srivastava, PhD⁴^*, Leslie L. Robison, PhD, MPH¹, Ching-Hon Pui, MD⁵, Melissa M. Hudson, MD^1,5 and Kevin R. Krull, PhD¹^*

¹Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
²Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN
³Children’s Hospital Los Angeles, Los Angeles, CA
⁴Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
⁵Oncology, St. Jude Children's Research Hospital, Memphis, TN

3256

Low Pre-Test Probability Scores Are Not Sufficient to Exclude Heparin-Induced Thrombocytopenia in Critically Ill Patients

Noppacharn Uaprasert, MD¹^*, Benjaporn Akkawat¹^*, Rattaporn Vichitratchaneekorn¹^*, Chantiya Chanswangphuwana, MD¹^* and Ponlapat Rojnuckarin, MD, PhD²

¹Medicine, Faculty of Medicine Chulalongkorn University, Bangkok, Thailand
²Dept. of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

3257

Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens

Leila Family, PhD¹^*, Su-Jau Yang¹^*, Zandra Klippel, MD², Yanli Li, MD, PhD²^*, John H Page, MD, ScD²^*, Roberto Rodriguez, MD³ and Chun Chao, PhD¹

¹Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA
²Amgen Inc., Thousand Oaks, CA
³Department of Hematology Oncology, Kaiser Parmanente Southern California, Los Angeles, CA

3258

Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation

Guy Pratt, MD FRCP FRCPath^1,2, Holly Cranmer, BSc³^*, Christine Almond, MSC, MMath³^*, Stephen Harding, PhD^4,5, Dale John Powner, PhD⁵^*, Richard Geir Hughes, DPhil⁵^* and Mark Cook, PhD, MBChb⁶^*

¹University of Birmingham, CRUK Institute for Cancer Studies, Birmingham, United Kingdom
²Heart of England NHS Trust, Birmingham, United Kingdom
³BresMed, Sheffield, United Kingdom
⁴Department of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
⁵The Binding Site Group Ltd, Birmingham, United Kingdom
⁶Haematology, University Hospitals Birmingham, Birmingham, United Kingdom

3259

Demographics and Long-Term Outcome of Incident Immune Thrombocytopenic Purpura: A Twelve-Years Nationwide Population-Based Study in Taiwan

Bor-Sheng Ko¹^*, Grace Hui-Min Wu^2,3^*, Yu-Chiao Wang²^*, Ming Yao, MD⁴^*, Churn-Shiouh Gau^5,6^*, Szu-Chun Hsu, MD⁷^*, Jih-Luh Tang, MD, PhD⁴ and Raoh-Fang Pwu^2,8^*

¹National Taiwan University Hospital, Taipei, Taiwan
²Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan
³Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan
⁴Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
⁵Center for Drug Evaluation, Taipei, Taiwan
⁶School of Pharmacy, National Taiwan University, Taipei, Taiwan
⁷Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
⁸School of Health Care Administration, Taipei Medical University, Taipei, Taiwan

3260

Accuracy of Administrative Coding for Sickle Cell Disease

Michelle Ting, M.D.¹^*, Shyamli Sinha, M.D.¹^* and Timothy L. McCavit, MD²

¹Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
²Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX

3261

Comorbidities Drive Outcomes for Both Malignancy and Non-Malignancy Associated Hemophagocytic Syndrome

Benny Johnson, DO¹^*, Smith Giri, MBBS², Sara E. Nunnery²^*, Eric Wiedower, DO¹, Omer Jamy, MD²^*, Jason C. Chandler, MD³ and Mike G. Martin, MD³

¹Division of Hematology/Oncology, Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN
²Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN
³Hematology/Oncology, The West Cancer Center/The University of Tennessee Health Science Center, Memphis, TN

3262

Inpatient Utilization Among Children and Adolescents with Sickle Cell Disease: Analysis of a Large Populated-Based Retrospective Cohort

Rodney Theodore, MPH¹^*, Vaughn Barry, PhD, MPH², Maa-Ohui Quarmyne, MBChB MS³, Carlton Dampier, MD, CPI⁴ and Peter A. Lane, MD³

¹Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
²Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
³Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA
⁴Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA

3263

Contraceptive in Women with Sickle Cell Disease: A Survey Study

Natalie S Whaley, MD, MPH¹^*, Sophie Lanzkron, MD, MHS² and Anne Burke, MD, MPH³^*

¹University of Rochester, Rochester, NY
²Department of Medicine, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD
³Johns Hopkins University, Baltimore

3264

Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey

Jamile M. Shammo, MD¹, Rachel L Mitchell, MD¹, Kylene Ogborn, RN¹^*, Ellen Salkeld²^* and Stephanie Chisolm, PhD,³^*

¹Section of Hematology, Rush University Medical Center, Chicago, IL
²Aplastic Anemia and MDS International Foundation, Rockville, MD
³Bladder Cancer Advocacy Network (BCAN), Bethesda, MD

3265

The Association of Iron Deficiency and Fatigue in Non-Anemic Females of Childbearing Age: An Nhanes Analysis

Mohamed Akkad, MD¹^*, Mohammed Shaik, MD, MS²^* and Anas Al-Janadi, MD³

¹Michigan State University, Lansing, MI
²Breslin Cancer Center, Lansing, MI
³Breslin Cancer Center, MSU, Lansing, MI

3266

Radiologist-Performed Musculoskeletal Ultrasound (MSKUS) for Evaluation of Joint and Soft Tissue Pain Episodes in Patients with Bleeding Disorders

Anjlee Mahajan, MD¹, Patricia Tobase, PT, DPT²^*, Andrew Phelps, MD³^*, Darcy Phelan, RN, MS, NP¹^*, Mary B. Lesh, CNP, MS, NP⁴^* and Adam Giermasz, MD, PhD¹

¹Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA
²Department of Physical Therapy and Rehab Science, University of California, San Francisco, San Francisco, CA
³Department of Radiology, University of California, San Francisco, San Francisco, CA
⁴Division of Pediatric Hematology, University of California, San Francisco, San Francisco, CA

3267

Acute Care in the Emergency Department Differs before and after Transition for Adolescents and Young Adults with Sickle Cell Disease

Nathan R. Stehouwer, M.D.¹^*, Bohyung Park²^*, Preston Edge²^*, Hong Li, M.S.²^*, Connie M. Piccone, MD² and Jane A. Little, M.D.³

¹Case Western Reserve University/University Hospitals Case Medicine Center and Rainbow Babies & Children's Hospital, Cleveland, OH
²Case Western Reserve University, Cleveland, OH
³Division of Hematology/Oncology, CWRU/University Hospitals Seidman Cancer Center, Cleveland, OH

3268

Incidence of Major Hemorrhage Among CLL and MCL Patients Compared to the General Elderly Population: An Analysis of the US SEER-Medicare Linked Database

Dina M Gifkins, PhD, MPH¹^*, Amy Matcho, BSc¹^*, Huiying Yang, PhD, MD²^*, Yimei Xu, MD¹^*, Mary Ann Gooden, MD²^* and Mark Wildgust, PhD¹

¹Janssen Pharmaceuticals, Inc., Raritan, NJ
²Pharmacyclics, Inc., Sunnyvale, CA

3269

Perception of Actual Factor Concentrates and Expectations Towards Future Treatment with New Long-Lasting Products - Results of a Survey Among Haemophilia Patients in Germany - Analysis of Open Questions

Werner Kalnins¹^*, Wolfgang A. Miesbach, MD, PhD² and Sylvia von Mackensen, PhD³^*

¹German Haemophilia Society (DHG), Hamburg, Germany
²Haemophilia Centre, University Hospital Frankfurt, Frankfurt, Germany
³Institute of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

3270

Costs of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens

Tiffany P. Quock, PhD, MS¹^*, Michael S. Broder, MD, MSHS²^*, Eunice Chang, PhD²^*, Sheila R. Reddy, PhD, MS, RPh²^*, Sally Arai, MD³, Rajni Agarwal-Hashmi, MD³^* and Kathleen F. Villa, MS¹^*

¹Jazz Pharmaceuticals, Palo Alto, CA
²Partnership for Health Analytic Research, LLC, Beverly Hills, CA
³Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA

3271

Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database

Michael Wang, MD¹, Anissa Cyhaniuk, MS²^*, David L Cooper, MD, MBA³ and Neeraj N Iyer, PhD⁴^*

¹University of Colorado School of Medicine, Aurora, CO
²AC Analytical Solutions, Barrington, IL
³Novo Nordisk Inc., Plainsboro, NJ
⁴Novo Nordisk Inc., Plainsboro, NJ

3272

Medical and Economic Burden of Heparin-Induced Thrombocytopenia: Data from the National Inpatient Sample 2009-2011

Ranjan Pathak, MD¹, Smith Giri, MBBS², Madan Raj Aryal, MD¹^*, Paras Karmacharya, MD³^*, Anthony Donato, MD MHPE³^* and Vijaya R. Bhatt, MD⁴

¹Reading Health System, West Reading, PA
²Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN
³Reading Health System, wyomissing, PA
⁴Hematology-Oncology, University of Nebraska Medical Center/Nebraska Medicine, Omaha, NE

3273

A Model Estimating Indirect Costs of Premature Death Associated with Severe Hepatic Veno-Occlusive Disease (sVOD) Among Hematopoietic Stem Cell Transplant (HSCT) Patients in the United States (U.S.)

Tiffany P. Quock, PhD, MS¹^*, Zheng-Yi Zhou, PhD²^*, Byran Dai, MS²^*, Wenxi Tang, MS²^* and Kathleen F. Villa, MS¹^*

¹Jazz Pharmaceuticals, Palo Alto, CA
²Analysis Group, New York, NY

3274

Cost of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States

Junji Lin, PhD¹^*, Xinke Zhang, MS^1,2^*, Xiaoyan Li, PhD¹^*, Ivy Altomare, MD³^*, Jeffrey S Wasser, MD^4,5 and Karynsa Cetin, MPH⁶^*

¹Amgen Inc., Thousand Oaks, CA
²University of Southern, Los Angeles, CA
³Division of Medical Oncology, Duke University Medical Center, Durham, NC
⁴Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine, Farmington, CT
⁵Department of Medicine, Division of Hematology-Oncology, University of Connecticut School of Medicine, Farmington, CT
⁶Amgen Inc., Cambridge, MA

3275

Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy

Martha E. Stutsky, PharmD, BCPS¹^*, David P. Reardon, PharmD, BCPS¹^* and Alfred I Lee, MD, PhD²

¹Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT
²Hematology, Yale University School of Medicine, New Haven, CT

3276

Use of Institutional Clinical Care Guidelines to Determine HA-VTE Risk Level for Consideration of Thromboprophylaxis in Hospitalized Children

Natalie Laing Smith, BS^*, Kelsey Fowlkes, BS^*, Beth Boulden Warren, MD, MS, Beth Wathen, MSN, PNP, CCRN^*, Bryce Clark, RN, MPA, CPHQ^*, Joanne M. Hilden, MD, Daniel Hyman, MD, MMM^*, Marilyn J. Manco-Johnson, MD and Brian R. Branchford, MD

Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO

3277

The Appropriateness of Heparin Antibody Testing. A Single Institution Retrospective Analysis

Danny A. Landau, MD¹, Nadezhda Kholodnaya²^*, Ana CuestaFernandez³^* and Ariel PerezPerez¹^*

¹Orlando Health, Orlando, FL
²UF Health Cancer Center Orlando Health, Orlando, FL
³University of Florida Cancer Center Orlando Health, Orlando, FL

3278

Beta-Thalassemia Treatment and Complications in Two Large US Insured Population Databases

Nancy Maserejian, ScD^*, Li Li, MS^*, Jin Wang, MS^*, William E. Hobbs, MD/PhD and Catherine Madigan, MD^*

Biogen, Cambridge, MA

3279

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Elliott P. Vichinsky, MD¹, Janet Kwiatkowski, MD², Patricia J. Giardina, MD³, Carole Paley, MD⁴, Francis Vekeman, MA⁵^*, Wendy Y. Cheng, MPH, MPhil⁶^*, Joseph Damron, BA⁶^*, Nora McCormick, MSc⁶^*, Medha Sasane, PhD, BPharm, MS⁴^*, Ying Qiu, PhD⁴^*, Mei Sheng Duh, MPH, ScD⁶ and Alexis A. Thompson, MD⁷

¹Children's Hospital and Research Center Oakland, Oakland, CA
²Children's Hospital of Philadelphia, Philadelphia, PA
³Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY
⁴Novartis Pharmaceuticals, East Hanover, NJ
⁵Groupe d’analyse, Ltée, Montreal, Canada
⁶Analysis Group, Inc., Boston, MA
⁷Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

3280

Incidence of Hepatic Veno-Occlusive Disease (VOD) in Premier Healthcare Database

Christopher C. Dvorak, MD¹, Bijan Nejadnik, MD², Zhun Cao, PhD³^*, Craig Lipkin, MS³^*, Scott B. Robinson, MA, MPH³^* and Kathleen F. Villa, MS²^*

¹University of California San Francisco Benioff Children’s Hospital, San Francisco, CA
²Jazz Pharmaceuticals, Palo Alto, CA
³Premier Research Services, Charlotte, NC

3281

Detection of Mild Clotting Factor Deficiencies. Critical Role of the Activated Partial Thromboplastin Time (aPTT) Reagent

Pierre A. Toulon¹, Yaelle Eloit¹^*, Motalib Smahi²^*, Didier Jambou¹^*, Anny Appert-Flory¹^* and Florence Fischer¹^*

¹Hematology, University Hospital Pasteur, Nice, France
²Hematology, Simone Veil Hospital, Montmorency, France

See more of: Health Services and Outcomes Research – Non-Malignant Conditions
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

901. Health Services and Outcomes Research – Non-Malignant Conditions: Poster II